1. Wewer MD, Zhao M, Nordholm-Carstensen A, Weimers P, Seidelin JB, Burisch J. The incidence and disease course of perianal Crohn’s disease: a Danish nationwide cohort study, 1997-2015. J Crohns Colitis 2021;15:5–13.
2. Gajendran M, Loganathan P, Catinella AP, Hashash JG. A comprehensive review and update on Crohn’s disease. Dis Mon 2018;64:20–57.
3. Shi HY, Levy AN, Trivedi HD, Chan FKL, Ng SC, Ananthakrishnan AN. Ethnicity influences phenotype and outcomes in inflammatory bowel disease: a systematic review and meta-analysis of population-based studies. Clin Gastroenterol Hepatol 2018;16:190–197.e11.
4. Kaur M, Dalal RL, Shaffer S, Schwartz DA, Rubin DT. Inpatient management of inflammatory bowel disease-related complications. Clin Gastroenterol Hepatol 2020;18:1346–1355.
5. Adegbola SO, Dibley L, Sahnan K, et al. Burden of disease and adaptation to life in patients with Crohn’s perianal fistula: a qualitative exploration. Health Qual Life Outcomes 2020;18:370.
6. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999;340:1398–1405.
7. Lichtiger S, Binion DG, Wolf DC, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy. Aliment Pharmacol Ther 2010;32:1228–1239.
8. Panés J, Rimola J. Perianal fistulizing Crohn’s disease: pathogenesis, diagnosis and therapy. Nat Rev Gastroenterol Hepatol 2017;14:652–664.
9. Meima-van Praag EM, van Rijn KL, et al. Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn’s disease (PISA-II): a patient preference randomised trial. Lancet Gastroenterol Hepatol 2022;7:617–626.
10. Badla O, Goit R, Saddik SE, et al. The multidisciplinary management of perianal fistulas in Crohn’s disease: a systematic review. Cureus 2022;14:e29347.
11. Laland M, François M, D’Amico F, et al. Identification of the optimal medical and surgical management for patients with perianal fistulising Crohn’s disease. Colorectal Dis 2023;25:75–82.
12. Ye BD, Jang BI, Jeen YT, Lee KM, Kim JS, Yang SK, IBD Study Group of the Korean Association of the Study of Intestinal Diseases. [Diagnostic guideline of Crohn’s disease]. Korean J Gastroenterol 2009;53:161–176Korean.
13. Koh SJ, Hong SN, Park SK, et al.; IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Korean clinical practice guidelines on biologics for moderate to severe Crohn’s disease. Intest Res 2023;21:43–60.
14. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749–753.
15. Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet 1980;1:514.
16. Panes J, Bouhnik Y, Reinisch W, et al. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis 2013;7:556–585.
17. Steinhart AH, Panaccione R, Targownik L, et al. Clinical practice guideline for the medical management of perianal fistulizing Crohn’s disease: the Toronto consensus. Inflamm Bowel Dis 2019;25:1–13.
18. Juncadella AC, Alame AM, Sands LR, Deshpande AR. Perianal Crohn’s disease: a review. Postgrad Med 2015;127:266–272.
19. Schober P, Boer C, Schwarte LA. Correlation coefficients: appropriate use and interpretation. Anesth Analg 2018;126:1763–1768.
20. Atia O, Focht G, Lujan R, et al. Perianal Crohn disease is more common in children and is associated with complicated disease course despite higher utilization of biologics: a population-based study from the epidemiology group of the Israeli IBD Research Nucleus (epiIIRN). J Pediatr Gastroenterol Nutr 2022;74:788–793.
21. Allan A, Linares L, Spooner HA, Alexander-Williams J. Clinical index to quantitate symptoms of perianal Crohn’s disease. Dis Colon Rectum 1992;35:656–661.
22. Irvine EJ. Usual therapy improves perianal Crohn’s disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995;20:27–32.
23. Pikarsky AJ, Gervaz P, Wexner SD. Perianal Crohn disease: a new scoring system to evaluate and predict outcome of surgical intervention. Arch Surg 2002;137:774–777discussion 778.
24. Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology 2002;122:875–880.
25. Gecse KB, Sebastian S, Hertogh Gd, et al. Results of the fifth scientific workshop of the ECCO [II]: clinical aspects of perianal fistulising Crohn’s disease-the unmet needs. J Crohns Colitis 2016;10:758–765.
26. García-Olmo D, García-Arranz M, Herreros D, Pascual I, Peiro C, Rodríguez-Montes JA. A phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 2005;48:1416–1423.
27. Barreiro Domínguez EM, Vázquez-García I, Pérez-Corbal L, Ballinas Miranda JR, Antelo JS, Parajó Calvo A. Mesenchymal stem cells for the treatment of perianal fistulizing Crohn’s disease-a video vignette. Colorectal Dis 2022;24:1441–1442.
28. Tanaka S, Matsuo K, Sasaki T, et al. Clinical advantages of combined seton placement and infliximab maintenance therapy for perianal fistulizing Crohn’s disease: when and how were the seton drains removed? Hepatogastroenterology 2010;57:3–7.
留言 (0)